Deal facts
- Buyer
- Lixte Biotechnology Holdings, Inc.
- Target
- Nomad Transportable Power Systems, Inc.
- Deal value
- Not disclosed
- Announced
- 2 July 2026
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares, cash
Sources
Lixte Biotechnology Holdings, Inc. has agreed to acquire Nomad Transportable Power Systems, Inc. in a strategic acquisition within the Healthcare sector. The transaction involves a mixed consideration structure comprising both shares and cash, though the specific deal value remains undisclosed. Both the acquiring entity and the target are based in the United States, indicating a domestic consolidation of assets within the same national market. The deal was announced on 2 July 2026, with the transaction officially completing on the preceding day, 1 July 2026. This timeline suggests a rapid execution process where the legal completion preceded the public announcement by a single day. The high confidence ratings attached to the parties and the sector classification confirm the accuracy of these details. The transaction is now considered fully completed and no longer subject to pending regulatory conditions.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
Lixte Biotechnology Holdings, Inc. completes acquisition of Nomad Transportable Power Systems, Inc.
Item 1.01 Entry into a Material Definitive Agreement. On June 11, 2026, Lixte Biotechnology Holdings, Inc., (the “Company”), Nomad Transportable Power Systems, Inc (“NOMAD”) and NBD Merger Sub, Inc., (“Merger Sub”), entered into a Merger Agreement (the “Merger Agreement”), pursuant to which Merger Sub is to be merged with and into NOMAD, with NOMAD surviving as a wholly-owned subsidiary of the Com
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
GSK plc to acquire Nuvalent, Inc
GSK plc has agreed to acquire Nuvalent, Inc in a strategic acquisition valued at $10.6 billion. The transaction, announced and completed on 15 July 2026, involves full c…
- Buyer
- GSK plc
- Target
- Nuvalent, Inc
- Deal value
- USD 10,600,000,000
- Deal type
- strategic acquisition
Volex plc to acquire Kepler SignalTek Ltd
Volex plc has agreed to acquire Kepler SignalTek Ltd, a healthcare sector business based in the United Kingdom. The strategic acquisition was announced and completed on…
- Buyer
- Volex plc
- Target
- Kepler SignalTek Ltd
- Deal value
- USD 89,400,000
- Deal type
- strategic acquisition
Public Company Management Corporation to acquire Physicians Capital Management Corporation
Public Company Management Corporation has agreed to acquire Physicians Capital Management Corporation in a strategic acquisition within the healthcare sector. The transa…
- Buyer
- Public Company Management Corporation
- Target
- Physicians Capital Management Corporation
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Liminatus Pharma, Inc. to acquire InnocsAI LLC
Liminatus Pharma, Inc. has agreed to acquire InnocsAI LLC in a strategic acquisition within the healthcare sector. The transaction involves a share-based consideration s…
- Buyer
- Liminatus Pharma, Inc.
- Target
- InnocsAI LLC
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Buyer history
Lixte Biotechnology Holdings, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive